EMVision Medical Devices Ltd

CHIA:EMV Stock Report

Market Cap: AU$160.8m

EMVision Medical Devices Management

Management criteria checks 3/4

EMVision Medical Devices' CEO is Scott Kirkland, appointed in Jul 2023, has a tenure of 1.5 years. total yearly compensation is A$557.06K, comprised of 56.5% salary and 43.5% bonuses, including company stock and options. directly owns 5% of the company’s shares, worth A$8.04M. The average tenure of the management team and the board of directors is 3 years and 5.6 years respectively.

Key information

Scott Kirkland

Chief executive officer

AU$557.1k

Total compensation

CEO salary percentage56.5%
CEO tenure1.5yrs
CEO ownership5.0%
Management average tenure3yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Scott Kirkland's remuneration changed compared to EMVision Medical Devices's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$557kAU$315k

-AU$3m

Mar 31 2024n/an/a

-AU$3m

Dec 31 2023n/an/a

-AU$3m

Sep 30 2023n/an/a

-AU$4m

Jun 30 2023AU$285kAU$258k

-AU$4m

Mar 31 2023n/an/a

-AU$4m

Dec 31 2022n/an/a

-AU$5m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022AU$270kAU$245k

-AU$6m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021n/an/a

-AU$7m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$262kAU$240k

-AU$8m

Mar 31 2021n/an/a

-AU$7m

Dec 31 2020n/an/a

-AU$5m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$224kAU$205k

-AU$3m

Mar 31 2020n/an/a

-AU$3m

Dec 31 2019n/an/a

-AU$3m

Sep 30 2019n/an/a

-AU$3m

Jun 30 2019AU$213kAU$150k

-AU$3m

Mar 31 2019n/an/a

-AU$3m

Dec 31 2018AU$45kAU$41k

-AU$2m

Compensation vs Market: Scott's total compensation ($USD345.38K) is about average for companies of similar size in the Australian market ($USD285.80K).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


CEO

Scott Kirkland

1.5yrs

Tenure

AU$557,063

Compensation

Mr. Scott Kirkland has been an Executive Director of EMvision Medical Devices Limited since July 11, 2017 and serves as its Chief Executive Officer and Managing Director since July 01, 2023. Mr. Kirkland h...


Leadership Team

NamePositionTenureCompensationOwnership
Scott Kirkland
CEO, MD & Executive Director1.5yrsAU$557.06k5%
A$ 8.0m
Emma Waldon
CFO & Company Secretary7.4yrsno data1.36%
A$ 2.2m
Forough Khandan
Chief Technology Officer2yrsno datano data
Stuart Crozier
Chairman of Clinical Advisory Board & Chief Scientific Officer4.1yrsno data1.22%
A$ 2.0m
Robert Tiller
Head of Design3.9yrsno datano data
Konstanty Bialkowski
Head of Tech Developmentno datano datano data
Christian Wight
Head of Regulatory Affairs1.8yrsno datano data

3.0yrs

Average Tenure

Experienced Management: EMV's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Kirkland
CEO, MD & Executive Director7.5yrsAU$557.06k5%
A$ 8.0m
Stuart Crozier
Chairman of Clinical Advisory Board & Chief Scientific Officer5.6yrsno data1.22%
A$ 2.0m
Geoffrey Donnan
Ex-Officio Member of Clinical Advisory Board2.8yrsno datano data
Philip Dubois
Independent Non-Executive Director4.3yrsAU$55.50k0.056%
A$ 89.3k
John Keep
Non-Executive Chairman6.8yrsAU$105.45k2.42%
A$ 3.9m
Geoffrey Richard Pocock
Non-Executive Director6.8yrsAU$55.50k1.0%
A$ 1.6m
Tony Keane
Independent Non-Executive Director6.6yrsAU$51.83k0.70%
A$ 1.1m
Michael O'Sullivan
Member of Clinical Advisory Board5.6yrsno datano data
David Cook
Member of Clinical Advisory Board5.6yrsno datano data
James Walsham
Member of Clinical Advisory Board5.6yrsno datano data
Ken Mitchell
Member of Clinical Advisory Board5.6yrsno datano data
Stephen Davis
Ex-Officio Member of Clinical Advisory Board2.8yrsno datano data

5.6yrs

Average Tenure

Experienced Board: EMV's board of directors are considered experienced (5.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 12:46
End of Day Share Price 2025/01/08 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EMVision Medical Devices Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anubhav SaxenaBell Potter